LeMaitre Vascular (LMAT) stock is experiencing a sharp pre-market plunge of 9% on Friday, following the company's fourth-quarter 2024 earnings report and disappointing first-quarter 2025 guidance released after the market close on Thursday.
The medical device maker reported Q4 2024 earnings per share (EPS) of $0.49, in line with analysts' estimates. However, the company's Q4 revenue of $55.7 million missed Wall Street's consensus estimate of $56 million. This revenue miss appears to be the primary driver behind the stock's steep decline in pre-market trading.
Adding to investor concerns, LeMaitre's Q1 2025 revenue guidance of $56.7-$58.7 million also fell short of analysts' expectations, further exacerbating the sell-off. While the company's Q1 EPS guidance range of $0.48-$0.53 was in line with estimates, the weak revenue outlook overshadowed this positive aspect, weighing heavily on the stock's performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.